Active — Not RecruitingPhase 2/3

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients

China29 participantsStarted 2022-07-13

Plain-language summary

To investigate the efficacy of Gonadotropin-releasing Hormone Agonist (GnRHa) plus letrozole in obese progestin-insensitive atypical endometrial hyperplasia (EAH) patients.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Megestrol acetate ≥ 160 mg qd using, combined with Levonorgestrel Lntrauterine System (LNG-IUS) inserted or not
✓. Medroxyprogesterone acetate ≥ 250 mg qd using, combined with LNG-IUS inserted or not
✓. LNG-IUS inserted
✓. remained with stable disease after 7 months of progestin use
✓. did not achieve CR after 10 months of progestin use

What they're measuring

Complete response (CR) rate within 28 weeks of treatment

Timeframe: Up to 28 weeks

Trial details

NCT IDNCT06390904

SponsorXiaojun Chen

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-07-30

View on ClinicalTrials.gov More Atypical Endometrial Hyperplasia trials